Tradestie Institutional Equity Comparison Engine
LYRA vs NVCT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
NVCT Overall Edge
NVCT Captures Institutional Edge (3โ0 Pillars ยท 7โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Nuvectis Pharma, Inc. Common Stock (NVCT) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, LYRA trades at N/M Forward P/E with -25032.0% operating margin (-87.2% YoY revenue) versus NVCT at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, LYRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against NVCT sits in BREAKDOWN (9th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
LYRA N/M vs NVCT N/M Fwd P/E
Growth & Margin Winner
NVCT
Op Margin -25032.0% vs 0.0% ยท YoY -87.2% vs +0.0%
Momentum & Technical Winner
NVCT
1Y -94.3% vs +216.8% ยท 52W Pos 1% vs 57%
Options & Structure Winner
NVCT
UNCLASSIFIED (N/A IV) vs BREAKDOWN (9th %ile IV)
LYRA
NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap
$2.3M
1M Return
-62.5%
1Y Return
-94.34%
Forward P/E
N/M
Unified AI Score
52.2 / 100
HOLD
Tech 60.0
Fund 56.0
Flow 50.0
Mom 59.0
NVCT
NASDAQ
Nuvectis Pharma, Inc. Common Stock
Pharmaceutical Preparations
$19.07
-0.21% 1D
Market Cap
$696.0M
1M Return
+0.69%
1Y Return
+216.78%
Forward P/E
N/M
Unified AI Score
53.4 / 100
HOLD
Tech 58.0
Fund 59.0
Flow 66.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
LYRA -94.34%
NVCT +216.78%
Spread: +136.48 pp (NVCT Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
LYRA TTM Op. Margin: -25032.0%
NVCT TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LYRA vs NVCT. Trailing 12-month operating profitability (LYRA -25032.0% vs NVCT 0.0%) and valuation multiples (LYRA N/M vs NVCT N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | LYRA | NVCT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.3M | $696.0M | Larger Scale | NVCT |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -87.2% | +0.0% | Higher Growth | NVCT |
| Operating Margin (TTM) Profitability | -25032.0% | 0.0% | Higher Margin | NVCT |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -404.5% | -67.0% | Higher ROE | NVCT |
| 52-Week Range Position Momentum | 1% ($0โ$38) | 57% ($6โ$29) | Stronger Trend | NVCT |
| Beta / 30D Volatility Risk Regime | 0.33ฮฒ ยท 248% Vol | 0.70ฮฒ ยท 82% Vol | Lower Realized Risk | NVCT |
| Unified Institutional Score Composite Signal | 52.2 / 100 (HOLD) | 53.4 / 100 (HOLD) | Higher Composite | NVCT |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full LYRA vs NVCT Buy Guide
LYRA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
NVCT
BREAKDOWN
99d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
9th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither LYRA nor NVCT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.